

CASE 083

AUTHORS: Dr Himanshu Kataria

ACKNOWLEDGEMENT: Meghan Harrisson, Dr. Samriti Arora, Dr.Sambit K. Mohanty, Dr. Shivani Sharma.

CLINICAL HISTORY:

A 45-years-old gentleman diagnosed with locally advanced carcinoma of the left buccal mucosa.

DISEASE COURSE AND THE ROLE OF CANCERTAIN:

The patient was treated with 2 cycles of Docetaxel, Cisplatin, and Fluorouracil (TPF) till 23/08/2020. However, due to progressive disease, a wide local excision of the buccal mucosa, skin with left infrastructural maxillectomy, left hemimandibulectomy, and infratemporal fossa clearance was undertaken. A left modified neck dissection and right selective neck dissection was also performed. The face reconstruction was done using bipadelled free anterolateral thigh flap.

Histopathological examination showed a moderately differentiated squamous cell carcinoma, stage pT4aN3b, stage IV B with perineural invasion. Two of 35 lymph nodes isolated, showed metastatic deposits with extranodal extension.

The patient was subsequently given adjuvant concurrent chemoradiation of 66 Gy in 33 fractions with 4 cycles of Cisplatin till 2/12/2020. Subsequent PET CT scan (26/2/2021) was suggestive of progressive disease. A CanCertain chemosensitivity assay was conducted on 29/3/2021. The test showed the cancer cells to be sensitive to Epirubicin, Paclitaxel/Docetaxel, Palbociclib, and Gefitinib. PD-L1 immunohistochemistry was negative. In concordance with CanCertain suggested regimen, the patient was put on metronomic treatment for 10 months which was tolerated well by the patient, evident by 80% reduction in disease on CECT (14/12/2021). However, after 9 months, disease progression was noted in the form of lung metastases, but the patient remained asymptomatic at this time. The biopsy from right upper lobe lung lesion revealed a metastatic squamous cell carcinoma. Metronomic therapy was continued in accordance with the previous CanCertain regimen.